Last reviewed 2026-05-14 · How we verify

Anti-Beta Interferon (PF-06823859) (anti-beta-interferon-pf-06823859)

Anti-Beta Interferon (PF-06823859) is a marketed drug by Pfizer Inc. It targets the mechanism of action by inhibiting beta interferon. The key indications for this drug are Plaque Psoriasis and Psoriatic Arthritis. It has clinical differentiation due to its targeted mechanism of action. The commercial significance of this drug is its high revenue of 4.07B. There are no pipeline developments mentioned.

At a glance

Approved indications

• Plaque Psoriasis
• Psoriatic Arthritis

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• Aspirin
• Pentosan polysulfate
• Dabigatran
• Rivaroxaban
• Apixaban
• Edoxaban
• Cyclosporine
• Tacrolimus
• Sirolimus
• Everolimus
• Mycophenolate mofetil

Key clinical trials

• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] (PHASE3)
• An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-Beta Interferon (PF-06823859) CI brief — competitive landscape report
• Anti-Beta Interferon (PF-06823859) updates RSS · CI watch RSS
• Pfizer portfolio CI